Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Members of Congress Bought These 5 Stocks—Should You?

Five stocks recently traded by members of Congress—from AI defense to GLP-1 leaders—could offer clues for investors building their watchlists

MarketBeat

3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

‘I bought weight loss jabs on social media – this is why I regret it’

Doctor warns buying weight loss drugs from illegitimate sources like social media could be ‘life-threatening’

The Independent UK

The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

MarketBeat

Should You Chase the Rally in Hims & Hers Stock Today?

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Barchart

Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems

Eli Lilly CEO David Ricks said AI can’t quite solve complex scientific problems without advanced data.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

New oral pill beats previous alternatives and shows 8% weight loss in clinical trials

Eli Lilly’s new oral pill, orforglipron, led to up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives.

Euronews

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs

The Guardian - UK

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Barchart

Asian shares are mixed after heavy selling of potential AI losers hits Wall Street

Shares are mixed in Asia after U.S. stocks slumped on heavy selling of shares in companies that could be losers in the artificial-intelligence boom

The Independent UK

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

Barchart

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Axios

TrumpRx is live. Here's what the website shows

The site is a key part of President Trump's efforts to lower health costs but isn't expected to significantly affect drug prices.

MarketBeat

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

The Independent UK

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

Evening Standard

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

Barchart

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Euronews

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Barchart

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

The Independent UK

Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments

The Independent UK

Eye-stroke, vomiting and burst colon: Lawsuits accuse weight-loss drugs of severe side effects

Thousands of patients have filed lawsuits against drug producers claiming side effects - but the companies insist their products are properly tested

The Guardian - UK

Fake weight-loss medication in tablet form could flood Britain, experts warn

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.